Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis

被引：0
|
作者：
Brian J Schmidt
Fergal P Casey
Thomas Paterson
Jason R Chan
机构：
[1] Entelos Holding Corporation,
来源：
BMC Bioinformatics | / 14卷
关键词：
Drug development; Mechanistic modeling; Biosimulation; Patient population; Biomarker; Pharmaceutical research & development; Personalized medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] THE EFFECT OF RITUXIMAB BIOSIMILAR THERAPY ON THE EXPRESSION OF INTERFERON-STIMULATED GENES ("INTERFERON SIGNATURE") IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Avdeeva, A.
    Tchetina, E.
    Markova, G.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 542 - 542
  • [22] Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker
    Rodriguez-Carrio, Javier
    Alperi-Lopez, Mercedes
    Lopez, Patricia
    Ballina-Garcia, Francisco J.
    Suarez, Ana
    FRONTIERS IN IMMUNOLOGY, 2018, 8
  • [23] Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis
    Reynier, Frederic
    Petit, Fabien
    Paye, Malick
    Turrel-Davin, Fanny
    Imbert, Pierre-Emmanuel
    Hot, Arnaud
    Mougin, Bruno
    Miossec, Pierre
    PLOS ONE, 2011, 6 (10):
  • [24] HETEROGENEITY OF THE TYPE I INTERFERON SIGNATURE IN RHEUMATOID ARTHRITIS MAY ACCOUNT FOR DIFFERENCES IN ITS CLINICAL RELEVANCE
    Rodriguez-Carrio, J.
    Alperi-Lopez, M.
    Lopez, P.
    Ballina-Garcia, F. J.
    Suarez, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1220 - 1221
  • [25] Rheumatoid arthritis subgroup with type I interferon signature: comment on the article by Thurlings et al Reply
    Dellavance, Alessandra
    Mariz, Henrique de Ataide
    Sato, Emilia Inoue
    Coelho Andrade, Luis Eduardo
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4037 - 4038
  • [26] Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression.
    de Jong, Tamarah D.
    Vosslamber, Saskia
    Blits, Marjolein
    Wolbink, Gertjan
    Nurmohamed, Michael T.
    van der Laken, Connie J.
    Jansen, Gerrit
    Voskuyl, Alexandre E.
    Verweij, Cornelis L.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S916 - S916
  • [27] Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis
    Iwasaki, Takeshi
    Watanabe, Ryu
    Ito, Hiromu
    Fujii, Takayuki
    Okuma, Kenji
    Oku, Takuma
    Hirayama, Yoshitaka
    Ohmura, Koichiro
    Murata, Koichi
    Murakami, Kosaku
    Yoshitomi, Hiroyuki
    Tanaka, Masao
    Matsuda, Shuichi
    Matsuda, Fumihiko
    Morinobu, Akio
    Hashimoto, Motomu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
    Luebbers, Joyce
    Brink, Mikael
    de Stadt, Lotte A. van
    Vosslamber, Saskia
    Wesseling, John G.
    van Schaardenburg, Dirkjan
    Rantapaa-Dahlqvist, Solbritt
    Verweij, Cornelis L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (05) : 776 - 780
  • [29] B Cell Activation Biomarkers as Predictive Factors for the Response to Rituximab in Rheumatoid Arthritis
    Sellam, Jeremie
    Hendel-Chavez, Houria
    Rouanet, Stephanie
    Abbed, Karim
    Combe, Bernard
    Le Loet, Xavier
    Tebib, Jacques
    Sibilia, Jean
    Taoufik, Yassine
    Dougados, Maxime
    Mariette, Xavier
    ARTHRITIS AND RHEUMATISM, 2011, 63 (04): : 933 - 938
  • [30] REGULATION OF TYPE I INTERFERON SIGNATURE BY VGLL3 IN THE FIBROBLAST-LIKE SYNOVIOCYTES OF RHEUMATOID ARTHRITIS
    Du, Y.
    Dai, S. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1162 - 1162
12345